Hlorzoksazon
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| 5-hloro-3H-benzooksazol-2-on | |||
| Klinički podaci | |||
| Robne marke | Parafonforte | ||
| AHFS/Drugs.com | Monografija | ||
| MedlinePlus | a682577 | ||
| Identifikatori | |||
| CAS broj | 95-25-0 | ||
| ATC kod | M03BB03 | ||
| PubChem[1][2] | 2733 | ||
| DrugBank | DB00356 | ||
| ChemSpider[3] | 2632 | ||
| UNII | H0DE420U8G 
| ||
| KEGG[4] | D00771
| ||
| ChEBI | CHEBI:3655
| ||
| ChEMBL[5] | CHEMBL1371
| ||
| Hemijski podaci | |||
| Formula | C7H4ClNO2 | ||
| Mol. masa | 169,565 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakokinetički podaci | |||
| Bioraspoloživost | dobro je apsorbovan | ||
| Vezivanje za proteine plazme | 13–18% | ||
| Metabolizam | hepatic | ||
| Poluvreme eliminacije | 1,1 h | ||
| Izlučivanje | urine (<1%) | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
| Način primene | oralno | ||
Hlorzoksazon je centralno delujući miorelaksant, koji se koristi za tretiranje mušićnih spazama i rezultirajućeg bola ili neprijatnosti. On deluje na kičmenu moždinu. Hlorzoksazon je u prodaji pod imenima Muscol ili Parafon Forte, kao kombinacija sa acetaminofenom (Paracetamolom). Moguće nuspojave su: vrtoglavica, nepromišljenost, slabost, mučnina, povraćanje, i disfunkcija jetre.
Hlorzoksazon, 5-hloro-2-benzoksazolion, se može sintetisati reakcijom heterciklizacije 2-amino-4-hlorofenola sa fosgenom.
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- D.F. Marsh, U.S. Patent 2.895.877 (1959).
- Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF. (2006). „Chlorzoxazone inhibit contraction of rat thoracic aorta”. Eur J Pharmacol 545 (2–3): 161–6. DOI:10.1016/j.ejphar.2006.06.063. PMID 16859676.
- Park J, Kim K, Park P, Ha J (2006). „Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe”. J Clin Pharmacol 46 (1): 109–14. DOI:10.1177/0091270005282635. PMID 16397290.
- Wan J, Ernstgård L, Song B, Shoaf S (2006). „Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats”. J Pharm Pharmacol 58 (1): 51–61. DOI:10.1211/jpp.58.1.0007. PMC 1388188. PMID 16393464.
- PARAFON DSC (chlorzoxazone) tablet, Daily Med, U.S. National Library of Medicine